Irinotecan (HCl Trihydrate)

Drug #1160

Irinotecan (HCl Trihydrate) is an antineoplastic agent, also known as anticancer drugs. Irinotecan (HCl Trihydrate) is a semisynthetic derivative of alkaloid camptothecin. Irinotecan (HCl Trihydrate) is a pro-drug and is effective in the treatment of different cancers to slow or stop the growth of cancererous or abnormal cells. Irinotecan (HCl Trihydrate) is used in combination of different anticancer drugs to achieve best results and to reduce toxicity or side effects. It has been recently approved for clinical use.

← Previous drug Next drug →

Primary Characteristics

It is of Synthetic origin and belongs to Dipiperidine.

It belongs to DNA Strand Breakage pharmacological group on the basis of mechanism of action and also classified in Antineoplastic Agent, Plant Derivative , Antineoplastic Agent, Plant Derivative pharmacological group.

Molecular Weight: 677.2 · Solubility in Water: soluble · Non-proprietary name: Irinotecan (HCl Trihydrate).

Molecular structure of Irinotecan (HCl Trihydrate)

Pharmacokinetics

Distribution: Irinotecan (HCl Trihydrate) has a volume of distribution is 263. plasma protein binding is 30 - 68 %.

Elimination: it is metabolised via hepatic, plasma half-life is 10 hr, renal excretion is 16.7(15.7-17.7)%.

Indications

Irinotecan (HCl Trihydrate) is primarily indicated in conditions like Carcinoma of colon.

Irinotecan (HCl Trihydrate) is also indicated for secondary conditions like Metastatic colorectal cancer.

Contraindications

Irinotecan (HCl Trihydrate) is contraindicated in conditions like Bone marrow failure, Bowel obstruction.

Dosage

Irinotecan (HCl Trihydrate)'s dosage details are as follows:

Dose	Single Dose	Frequency	Route	Instructions
Adult Dosage
125 – 350 mg/sq.meter	—	—	IV Inf	As recomemnted,Over30-90 min., every 3-4 week
Paediatric Dosage (20kg)
0 – 0	—	—		Not recommended in this age group
Neonatal Dosage (3kg)
0 – 0	—	—		Not recommended in this age group

Drug Interactions

5 interactions

Always consult your physician for the change of dose regimen or an alternative drug of choice that may strictly be required.

Side Effects

Irinotecan (HCl Trihydrate) in overdosage may give rise to further complications which include Thrombocytopenia , Neutropenia , Cholinergic crises , Diarrhea, Anaemia .

Irinotecan (HCl Trihydrate) is known to cause more or less tolerable side effects which are usually transient. These include Alopecia, Anorexia , Constipation , Diarrhea, Fever, Hypersalivation , Mucositis, Nausea and vomiting, Neutropenia, Sweating .

Warnings / Precautions

Irinotecan should be used with caution in patients with history, including any allergy (especially drug allergies), history of radiation treatments, diabetes, liver or lung disease. Use of laxatives should be avoided since Irinotecan may cause diarrhea. Limit alcohol intake since it may aggravate side effects. To avoid dizziness and lightheadedness, get up slowly, when rising from a seated or lying position. This drug is not recommended for use during pregnancy or lactation. Caution is advised when this drug is used in the elderly.

Interference in Pathology

Irinotecan (HCl Trihydrate) may interfere in the diagnosis of Monitoring of hematologic profile.

Available Brands

Click on a strength to view available brands.

Single Ingredient

Inj

100 mg 40 mg

Storage Conditions

Irinotecan (HCl Trihydrate) should be stored Inj.

Drug Classification

1.8.2 — Cytotoxic (anti-neoplastic) drugs

Manufacturers

Manufacturers of Irinotecan (HCl Trihydrate) in Pakistan:

Atco CCL Medinet Novartis ONCOGENE Pfizer